Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METLung: Onartuzumab + Erlotinib in MET+ NSCLC
NCT02031744Phase 3Completed
- Sponsor
- Roche
- Start
- Jan 2014
- Primary completion
- Jan 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of onartuzumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Roche. Primary endpoints: Overall Survival at 36 months and Incidence of Adverse Events at 33 months. Started Jan 2014; status: completed.
02
Drugs
onartuzumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02031744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02031744.